Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ambroxol as a Disease-modifying Treatment to Reduce the Risk of Cognitive Impairment in GBA-associated Parkinson's Disease. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial

NCT05287503 is registered in ClinicalTrials.gov with Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta as lead sponsor.

NCT NCT05287503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05287503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ambroxol as a Disease-modifying Treatment to Reduce the Risk of Cognitive Impairment in GBA-associated Parkinson's Disease. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial
Lead sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Phase
Phase 2
Overall status
Completed
Start date
March 9, 2022
Completion date
December 20, 2024
Enrollment
65 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gba gene mutation, parkinson disease